Volume 2, Number 4—October 1996
Synopsis
New Vaccines for the Prevention of Pneumococcal Infections
Helena Käyhty
and Juhani Eskola
and Juhani Eskola
Table 1
Pneumococcal conjugate vaccines in phase-II and phase-III trials
| Vaccine | Serotype | Carrier | Manufacturer |
|---|---|---|---|
| PncCRM | 4, 6B, 9V, 14, 18C, 19F, 23F | CRM197 | Wyeth-Lederle Vaccines and Pediatrics |
| PncD | 3, 4, 6B, 9V, 14, 18C, 19F, 23 | Diphtheria toxoid | Connaught Laboratories |
| PncT | 3, 4, 6B, 9V, 14, 18C, 19F, 23 | Tetanus toxoid | Pasteur Merieux Serums & Vaccins |
| PncOMPC | 4, 6B, 9V, 14, 18C, 19F, 23F | Meningococcal OMPC | Merck Research Laboratories |
CRM = CRM197, a nontoxic variant of diphtheria toxin; D = diphtheria toxoid; T = tetanus toxoid; OMPC = outer membrane protein complex
Page created: December 21, 2010
Page updated: December 21, 2010
Page reviewed: December 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.